We performed a research on PubMed/Medline, Cochrane library and Scopus using the keywords, “prostate cancer systemic treatment“, or, “nonmetastatic castration-resistant prostate cancer treatment”, or, “metastatic hormone-sensitive treatment”, or, “metastatic castration-resistant prostate cancer treatment”, or, “antibody–drug conjugates”, or, “STEAP-1” OR “TROP2” OR “PSMA” OR “CD46”, or, “B7-H3”. Here, TACSTD2 is linked to prostate carcinoma.